Bioavailability Enhancement Technologies and Services Market, 2020-2030
Low bioavailability is one of the primary concerns associated with marketed drugs; in fact, various studies indicate that around 40% of available drugs are poorly bioavailable / soluble. As the drug developers shift their focus towards development of lipophilic drug compounds, the issue with aqueous solubility / bioavailability of the drugs is likely to increase further. It is estimated that around 90% of NCEs belong to BCS class II and IV, which are known to be associated with low solubility / permeability. Given that a large number of drugs fail to reach the market due to poor bioavailability, the industry is looking for various tools / methods to mitigate this challenge. Moreover, as many companies seek to re-formulate existing product candidates that exhibit poor bioavailability (via the 505(b)(2) pathway), the demand for novel bioavailability enhancement methods has grown significantly.
Related Bookmarks
- Antibody Contract Manufacturing Market across Type of Antibodies (Monoclonal Antibodies, Bispecific
- HAIR LOSS PROBLEM?
- Human Microbiome Market: Focus on Therapeutics (including gut-brain axis targeting drugs)
- Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finis
- Effective ways to Cure a Toothache during pregnancy
- Get Proton Therapy for Lung Cancer
- Things You Must Know Before Getting Porcelain Dental Veneers
- Best Cancer Surgeon in Chandigarh
- What Is Naturopathic Medicine And How It Works?
- Zopiclone 7.5mg online UK for Different Sleep Disorders
Recent Profiles
Slot5000
Yaar Win
Bgd11 It Com
Business Manager
Total Care Aba
Neugini Naturals
R.evolution
Retatrutide Qrp Nutrition 60mg
Psr Compliance
C168